Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 20/20 | 0.58 |
| ▸ | CCND1 | P24385 | 15/20 | 0.58 |
| ▸ | CCND3 | P30281 | 14/20 | 0.58 |
| ▸ | CCND2 | P30279 | 13/20 | 0.58 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.58 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.58 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.58 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.58 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.58 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.52 |
| ▸ | CDK2 | P24941 | 5/20 | 0.52 |
| ▸ | CDK6 | Q00534 | 4/20 | 0.51 |
| ▸ | CCNE2 | O96020 | 4/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.51 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.51 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.51 |
| ▸ | CDK1 | P06493 | 3/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.51 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7710738 | 0.87 | CDK4 (0.70) | CDK4CCND1CCND3CCND2FGFR1 | |
| SCHEMBL7713061 | 0.87 | CDK4 (0.71) | CDK4CCND1CCND3CCND2FGFR1 | |
| SCHEMBL7713224 | 0.85 | CDK4 (0.65) | CDK4CCND1CCND3CCND2FGFR1 | |
| SCHEMBL11977088 | 0.82 | CDK4 (0.61) | CDK4CCND1CCND3CCND2FGFR1 | |
| SCHEMBL20418758 | 0.81 | CDK4 (0.58) | CDK4CCND1CCND3CCND2FGFR1 | |
| SCHEMBL11977083 | 0.81 | CDK4 (0.69) | CDK4CCND1CCND3CCND2FGFR1 | |
| SCHEMBL7706831 | 0.78 | CDK4 (0.72) | CDK4CCND1CCND3CCND2FGFR1 | |
| SCHEMBL7708879 | 0.78 | CSF1R (0.71) | CDK4CCND1CCND3CCND2FGFR1 | |
| SCHEMBL7706828 | 0.77 | CDK4 (0.73) | CDK4CCND1CCND3CCND2FGFR1 | |
| SCHEMBL7714624 | 0.77 | CDK4 (0.70) | CDK4CCND1CCND3CCND2FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180207163-A1 | Methods and compositions for treating solid tumors and other malignancies | NOVARTIS AG (CH) | 2018-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180207163-A1 | Methods and compositions for treating solid tumors and other malignancies | CDK4, CDK6, MTOR | CDK4 1/4885CCND1 76/4885CCND3 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.